Trial reportJournal of hypertension2026
Initial systolic blood pressure, antihypertensive treatment timing and outcomes in acute ischemic stroke: a subgroup analysis of CATIS-2 trial.
Trial report in Journal of hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03479554 (China Antihypertensive Trial in Acute Ischemic Stroke II), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
China Antihypertensive Trial in Acute Ischemic Stroke II
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWhether initial systolic blood pressure (SBP) influences blood pressure management in acute ischemic stroke (AIS) and its association with outcome remains inconclusive. We conducted a subgroup analysis of CATIS-2 trial (China Antihypertensive Trial in Acute Ischemic Stroke II) to assess the impact of early vs. delayed antihypertensive treatment in AIS, stratified by baseline SBP.
methodsCATIS-2 was a multicenter, randomized trial enrolling AIS patients within 24-48 h after onset, presenting with SBP 140-219 mmHg and without reperfusion therapy. Participants were randomized to receive immediate antihypertensive treatment or delayed treatment initiated on day 8. The primary outcome was functional dependency or death (modified Rankin Scale score ≥3) at 90-day. Three prespecified baseline SBP subgroups (<160, 160-179, and ≥180 mm Hg) were analyzed.
results4802 patients (mean age 63.7 years, 65.0% male) were included, with baseline SBP < 160 mmHg ( n = 2233), 160-179 mmHg ( n = 1849), and ≥180 mmHg ( n = 720). Among patients with baseline SBP 160-179 mmHg, early antihypertensive treatment was associated with increased risk of primary outcome compared to delayed treatment [13.3% vs. 10.4%; odds ratio (OR) 1.32, 95% confidence interval (CI) 1.00-1.76]. This finding was not observed in the baseline SBP < 160 mmHg subgroup (OR 1.12, 95% CI 0.84-1.50) or ≥180 mmHg subgroup (OR 0.98, 95% CI 0.66-1.46). No significant differences were found in stroke recurrence or major vascular events between treatment strategies across SBP subgroups.
conclusionEarly antihypertensive treatment may increase the risk of functional dependency or death in AIS patients with moderately elevated baseline SBP. These findings provide valuable insights into clinical practice regarding individualized blood pressure management in AIS. Further research is warranted. REGISTRATION: ClinicalTrials.gov (NCT03479554).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.